Oric Pharmaceuticals, Inc. 4

Richard A. Heyman exercised 3,500 options at $1.60 and sold 13,100 Oric Pharmaceuticals (ORIC) common shares at $12.02 on July 24, 2026.

On July 24, 2026, Richard A. Heyman exercised a stock option to acquire 3,500 shares of Oric Pharmaceuticals, Inc. common stock at $1.60 per share and then sold a total of 13,100 shares at $12.02 per share in two separate transactions. The option exercise, which was fully vested and immediately exercisable, resulted in 45,300 shares of common stock held directly after the acquisition. The subsequent sales, executed under a Rule 10b5-1 trading plan, reduced his direct holdings to 38,300 shares and his indirect holdings, held through RAHD Capital, LLC over which he has voting and investment power, to 206,672 shares. Based on the reported prices, the exercise was valued at approximately $5,600 while the aggregate sale proceeds totaled about $157,462, leaving his combined direct and indirect beneficial ownership at an estimated value of roughly $2.95 million at the sale price level.

Filing Facts

CIK

1796280

Ticker

ORIC

Form

4

Source Type

fda

Accession

0001584759-26-000015

Alert Tier

6